+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy



Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy



Therapeutics and Clinical Risk Management 15: 323-335



With immunotherapy innovations for cancer treatment, in particular chimeric antigen receptor (CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage their toxicities are required. Anti-CD19 CAR T-cell therapy has revolutionized the treatment of relapsed/refractory pediatric and adult acute lymphoblastic leukemia and refractory adult non-Hodgkin lymphoma, resulting in the expanded use of CAR T cells in multicenter trials and as US FDA-approved products. Cytokine release syndrome (CRS) and CAR-associated neurotoxicity, which can occur independently or concurrently with CRS, are two potentially life-threatening toxicities of CAR T-cell therapy. In this review, we will focus on describing the pathophysiology behind CRS, the proposed definitions of and grading systems for CRS, and innovative options for treating this potentially lethal systemic inflammatory condition.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066598304

Download citation: RISBibTeXText

PMID: 30880998

DOI: 10.2147/tcrm.s150524


Related references

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Review of Hematology 12(3): 195-205, 2019

Management of cytokine release syndrome during chimeric antigen receptor-modified T cell therapy. Zhonghua Xue Ye Xue Za Zhi 38(10): 907-912, 2017

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem Cell Transplant (ASCT). Biology of Blood and Marrow Transplantation 21(2): S355-S356, 2015

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation 25(4): E123-E127, 2019

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood 130(23): 2569-2572, 2017

Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. British Journal of Haematology 183(3): 364-374, 2018

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine 45(2): E124-E131, 2017

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21): 2295-2306, 2017

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. Journal of Hematology and Oncology 9(1): 70, 2016

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery 6(6): 664-679, 2016

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report. Medicine 97(7): E9992, 2018

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report. Medicine 97(16): E0455, 2018

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report: Erratum. Medicine 97(25): E11341-E11341, 2018

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist 23(8): 943-947, 2018

Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report. Clinical Cancer Research 25(1): 29-34, 2019